eligibility_summary
Eligible: patients with DLBCL, FL, or MCL who are CAR T–eligible and have had ≥1 prior therapy. Exclude: active HIV/HBV/HCV, uncontrolled infections, on treatment for another cancer, pregnant or breastfeeding, unable to take oral meds, significant recent events/conditions (e.g., stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm feasibility study combining: 1) Tazemetostat (Tazverik): an oral small‑molecule epigenetic therapy that selectively inhibits EZH2, the catalytic subunit of PRC2. Mechanism: reduces H3K27me3, de-represses genes, aiming to increase tumor antigen expression and antigen presentation, thereby enhancing immune recognition. 2) Standard-of-care autologous CAR T-cell therapy (typically anti‑CD19). Mechanism: engineered T cells recognize B‑cell antigens to trigger T‑cell activation and cytotoxic killing of malignant B cells. Targets/pathways: EZH2/PRC2 histone methylation axis in lymphoma cells, B‑cell surface antigen (commonly CD19) on malignant B cells, CAR-mediated T‑cell activation signaling. Intended to improve CAR T efficacy in DLBCL, FL, and MCL.